Penny Tom Biography and Net Worth

SVP Finance and Principal Accounting Officer of Equillium

Penny Tom joined Equillium in January 2019 and currently serves as Senior Vice President, Finance & Principal Accounting Officer. With more than 30 years of experience in financial reporting, finance operations, and Sarbanes-Oxley compliance, Ms. Tom has broad experience with both public and private companies in the life science industry, as well as Big 4 public accounting experience. Prior to joining Equillium, she held multiple corporate accounting and finance positions including experience with Illumina, Althea CMO, and Ernst & Young.

Ms. Tom received a Bachelor of Science in Accounting from the University of Montana – College of Business. Ms. Tom is a certified public accountant.

What is Penny Tom's net worth?: The estimated net worth of Penny Tom is at least $141.70 thousand as of May 28th, 2026. Ms. Tom owns 65,000 shares of Equillium stock worth more than $141,700 as of August 25th. This net worth estimate does not reflect any other investments that Ms. Tom may own. Learn More about Penny Tom's net worth.
How do I contact Penny Tom?: The corporate mailing address for Ms. Tom and other Equillium executives is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. Equillium can also be reached via phone at (858) 240-1200 and via email at [email protected]. Learn More on Penny Tom's contact information.
Has Penny Tom been buying or selling shares of Equillium?: Penny Tom has not been actively trading shares of Equillium during the last ninety days. Most recently, Penny Tom sold 65,000 shares of the business's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $2.95, for a transaction totalling $191,750.00. Following the completion of the sale, the insider now directly owns 65,000 shares of the company's stock, valued at $191,750. Learn More on Penny Tom's trading history.
Who are Equillium's active insiders?: Equillium's insider roster includes Stephen Connelly (Insider), Jason Keyes (CFO), and Penny Tom (SVP Finance and Principal Accounting Officer). Learn More on Equillium's active insiders.
Are insiders buying or selling shares of Equillium?: In the last twelve months, insiders at the sold shares 14 times. They sold a total of 1,044,195 shares worth more than $2,428,972.07. The most recent insider tranaction occured on June, 5th when COO Christine Zedelmayer sold 14,584 shares worth more than $42,731.12. Insiders at Equillium own 17.8% of the company. Learn More about insider trades at Equillium.
Information on this page was last updated on 6/5/2026.

Penny Tom Insider Trading History at Equillium

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/28/2026	Sell	65,000	$2.95	$191,750.00	65,000
1/8/2026	Sell	6,533	$1.29	$8,427.57
10/28/2024	Sell	2,835	$1.25	$3,543.75	6,533
10/25/2024	Sell	683	$1.25	$853.75	9,368
9/16/2024	Sell	38,806	$0.85	$32,985.10	10,051

Penny Tom Buying and Selling Activity at Equillium

Equillium Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Today's Range

Now: $2.18

$2.15

$2.24

50 Day Range

MA: $2.60

$2.01

$3.20

2 Week Range

Now: $2.18

$0.76

$3.54

Volume

606,005 shs

Average Volume

622,214 shs

Market Capitalization

$138.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83